- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline -
-
- The novel and proprietary CoMET platform is aimed at addressing Inherited Metabolic Diseases (IMDs) with deficit of energy metabolism and depletion of functional Coenzyme A (“CoA”)
- IMDs affect over 75,000 patients in the US and
Europe and are a significant cause of mortality in infants and young people - This modular technology has the potential to address multiple previously untreatable IMDs by targeting the key cellular dysfunctions that underlie these conditions. This approach would overcome important limitations of standard of care and has the potential to prevent the clinical progression of IMDs
- The CoMET platform leverages innovative chemistry with the goal of providing a stabilized CoA precursor and key metabolic intermediates to restore fundamental cellular metabolism
- Four distinct programs are currently in research, with plans to enter the clinic with the first program in the next 18 months
IMDs are severe rare genetic disorders caused by congenital defects of metabolism fundamental to energy generation and the survival of cells. In addition to disrupted energy production and the accumulation of toxic metabolites, these defects cause dysregulation of CoA, a core component of many metabolic pathways. As a result, IMDs are often fatal or highly life-impairing conditions that primarily affect children and currently have limited effective treatment options. We believe that the modular CoMET platform holds the potential to treat a wide variety of rare metabolic diseases by generating medicines that restore cellular metabolism.
The foundation of the proprietary technology is a stabilized CoA precursor backbone that has been shown in preclinical studies to supply functional CoA and carry tailored intermediary metabolite cargos. The modular technology targets multiple groups of IMDs that share a common metabolic pathway, independent of underlying genetic mutation. These include severe life-threatening disorders such as methylmalonic acidemia (MMA) and propionic acidemia (PA). Importantly, in preclinical studies, this technology has demonstrated the ability to provide both CoA and intermediate metabolites to all relevant organ systems affected by IMDs, including the liver, muscle and brain, thus bearing the potential to overcome some of the delivery limitations of other therapeutic approaches currently in development.
“The acquisition of the CoMET platform is in line with our core mission of developing disease-modifying treatments for rare severe diseases,” said
The transaction is expected to close by the end of
Topics to be addressed during the presentation include apraglutide’s development and potential in treating Short Bowel Syndrome with Intestinal Failure and Graft-versus-Host-Disease, and an overview of the Company’s new CoMET platform.
Members of VectivBio’s management team will be joined by external experts:
The live webcast of the presentation and the question-and-answer session will be accessible by visiting the “Events and Presentations” section of VectivBio’s website at https://ir.vectivbio.com/events-and-presentations. A dial-in number will also be provided closer to the event.
About
Forward Looking Statements
Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “near future,” “belief,” “guidance,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements concerning the consummation of the acquisition of Comet Therapeutics and the prospects of its platform, the success of development and commercialization efforts with respect to VectivBio’s product candidate and VectivBio’s plans to initiate additional clinical studies of apraglutide and to expand its rare disease product portfolio. All of such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond VectivBio’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the ability to satisfy the closing conditions and consummate the acquisition of Comet Therapeutics, the impacts of the ongoing COVID-19 pandemic, including interruptions or other adverse effects on clinical trials and delays in regulatory review; delay in or failure to obtain regulatory approval of VectivBio’s product candidate and successful compliance with FDA and other governmental regulations applicable to product approvals; the risks inherent in drug development and in conducting clinical trials; and those risks and uncertainties identified in the “Risk Factors” section of VectivBio’s Registration Statement on Form F-1 declared effective by the
For more information visit www.vectivbio.com, and follow us on LinkedIn and Twitter.
Investors
graham.morrell@vectivbio.com
Media
Morgan Warners
+1 (202) 295 0124
morgan.warners@fgh.com
Source:
2021 GlobeNewswire, Inc., source